Dublin, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "T-Cell Immunotherapy Market (2nd Edition), 2017-2030" report to their offering.
The "T-Cell Immunotherapy Market, 2017-2030 (2nd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders.
The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.
The role of academic players/research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), and LN-144 (Lion Biotechnologies/National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.
Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.
One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
6. T-Cell Receptor (TCR) Based Therapies
7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies
8. Market Opportunity
9. Key Therapeutic Areas for T-Cell Therapies
10. Emerging Technologies
11. Social Media: Emerging Trends
12. Partnerships and Collaborations
13. Venture Capital Support
14. Other T-Cell Immunotherapies
15. Case Study: Cell Therapy Manufacturing
16. T-Cell Immunotherapy: Cost Price Analysis
17. Company Profiles
18. Interview Transcripts
19. Conclusion
20. Appendix 1: Tabulated Data
21. Appendix 2: List of Companies and Organizations
- AGF Private Equity
- AJU IB Investment
- ARCH Venture Partners
- AURORA BioPharma
- AVG Ventures
- AbVitro
- AbbVie
- Abingworth
- AbraxisBioScience
- Adaptimmune
- Adicet Bio
- Advanced BioScience Laboratories
- Adverum Biotechnologies
- Affiliated Hospital to Academy of Military Medical Sciences
- AgonOx
- Agreen Biotech
- Alaska Permanent Fund
- Albert Einstein College of Medicine
- Alexandria Ventures
- Alexion Pharmaceuticals
- Allen Laboratories
- Allos Therapeutics
- Alpine Immune Sciences
- Alta Partners
- AltorBioScience
- Amgen
- Amsterdam BioTherapeutics Unit
- Antoni van Leeuwenhoek Hospital
- ApcethBiopharma
- Aquilo Capital Management
- Argos Therapeutics
- ArtaxBioPharma
- Astellas Pharma
- AstraZeneca
- Asymptote
- Atara Biotherapeutics
- Atlantic Bio GMP
- Atlas Venture
- Atreca Therapeutics
- Autolus
- Avidex
- BankInvest Biomedical Venture
- Batavia Biosciences
- Bavarian Nordic
- Baxalta
- Bayer
- Bayer Crop Sciences
- Baylor College of Medicine
- Beijing Doing Biomedical
- Bellicum Pharmaceuticals
- Bezos Expeditions
- Bill & Melinda Gates Foundation
- Bio Elpida
- BioLife Solutions
- BioNTech
- BioVeda China Fund
- Biogen
- Biomedical Catalyst
- Biomedical Catalyst Fund
- Biotecnol
- Bluebird bio
- Boehringer Ingelheim
- Boston Children's Hospital
- Bpifrance
- Brace Pharma Capital
- Breast International Group
- Bristol-Myers Squibb
- Broad Institute
- Broadfin Capital
- CARsgen Therapeutics
- CELLforCURE
- CHDI Foundation
- CRISPR Therapeutics
- Cabaret Biotech
- Caladrius Biosciences
- California Institute for Regenerative Medicine
- Cancer Prevention and Research Institute of Texas
- Cancer Research UK
- Cardiff University
- Caribou Biosciences
- Cartherics
- Casdin Capital
- Celgene
- Cell Design Labs
- Cell Medica
- Cell Therapies
- Cell Therapy and Cell Engineering Facility
- Cell and Gene Therapy Catapult
- Cellectis
- Cellular Biomedicine Group
- Cellular Therapeutics
- Celyad
- Centre for Cell Manufacturing Ireland
- Changzheng Hospital
- Charité - Universitätsmedizin Berlin
- Chengdu MedGenCell
- Children's Hospital of Philadelphia
- Children's Mercy Hospital Kansas City
- Chimeric Therapeutics
- Chinese PLA General Hospital
- Christie NHS Foundation Trust
- Chugai Seiyaku Kabushiki Kaisha
- City of Hope Medical Center
- Clough Capital Partners
- Cognate Bioservices
- Cold Genesys
- Columbia University
- Cooperative Research Center for Cell Therapy Manufacturing
- Corixa
- Cowen Group Investment
- Cystic Fibrosis Foundation Therapeutics
- Cytolumina Technologies
- Cytovance Biologics
- Dana-Farber Cancer Institute
- Dangdai International
- Dartmouth College
- Deerfield Management
- Delenex Therapeutics
- Dendreon
- Duke University
- Dutch Cancer Society
- ERS Genomics
- EUFETS
- Easton Capital
- EcoR1 Capital
- Editas Medicine
- Edmond Venture Capital
- Eisai
- Eli Lilly
- Endocyte
- Erasmus University Medical Center
- Eureka Therapeutics
- FCB-Pharmicell
- FGP Capital
- Fate Therapeutics
- Fetolumina Technologies
- Fidelity Biosciences
- Fidelity Management & Research Company
- Financière IDAT
- Finnish Innovation Fund
- Five Prime Therapeutics
- Flagship Ventures
- Fondazione Telethon
- Forbion Capital Partners
- Foresite Capital
- Formula Pharmaceuticals
- Fortress Biotech
- Franklin Templeton Investments
- FraunhoferInsitute for Cell Therapy and Immunology
- Fred Hutchinson Cancer Research Center
- Fuda Cancer Hospital
- GE Global Research
- Gadeta
- GammaCell Bio-Technologies
- Gene and Cell Therapy Lab
- Genentech
- GigaGen
- Gilead Sciences
- GlaxoSmithKline
- Google Ventures
- Great Ormond Street Hospital
- Green Cross Cell
- Griffin Securities
- Guy's and St Thomas' NHS Foundation Trust
- Généthon
- H. Lee Moffitt Cancer Center and Research Institute Hospital
- Hadassah Medical Organization
- Harvard University
- Heat Biologics
- Herlev Hospital
- Howard Hughes Medical Institute
- iCarTABBioMed
- iCell Therapeutics
- ImClone Systems
- Immatics
- Immune Therapeutics
- Immunex
- ImmunoCellular Therapeutics
- Immunocore
- Immunovative Therapies
- Imperial College London
- Imperial Innovations
- Innovative Cellular Therapeutics
- Innovative Genome Initiative
- Institut Curie (Curie Institute)
- Institut Pasteur (Pasteur Institute)
- Institute of Translational Health Sciences
- Intellia Therapeutics
- Intrexon
- Iowa State University
- JCR Pharmaceutical
- JIC GenesisFountain Healthcare Ventures
- JMP Securities
- JW Biotechnology
- Janssen Biotech
- Janus Capital Group
- Jennison Associates
- Jichi Medical University Hospital
- John Wayne Cancer Institute
- Johns Hopkins Kimmel Cancer Center
- Johns Hopkins University
- Johnson & Johnson
- Jolly Innovation Ventures
- Juno Therapeutics
- KTB Ventures
- Kaitai Capital
- Karolinska University Hospital
- Keio University School of Medicine
- Khosla Ventures
- King's College London- Rayne Cell Therapy Suite
- Kite Pharma
- Leiden University Medical Center
- Leucid Bio
- Lifeline Ventures Fund
- Ligand Pharmaceuticals
- Lilly Asia Ventures
- Lion Biotechnologies
- Lion TCR
- Lonza Biologics
- Loyola University
- Lymphoma and Leukemia Society
- MD Anderson Cancer Center
- MaSTherCell
- MabQuest
- Malin Corporation
- Massachusetts General Hospital
- Max DelbrückCenter for Molecular Medicine
- MaxCyte
- Mayo Clinic
- MedImmune
- MedPost Urgent Care
- Medarex
- Medicxi Ventures
- Medigene
- Memorial Sloan Kettering Cancer Center
- Merck
- Merck Serono
- Merlin Nexus
- Mie University
- Millennium Pharmaceuticals
- MiltenyiBiotec
- Mission Bay Capital
- MolMed
- Molecular and Cellular Therapeutics
- Morphotek
- Mustang Bio
- NIHR Oxford Biomedical Research Centre
- NantKwest (earlier Conkwest)
- NantWorks
- Nantes University Hospital
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National University of Ireland
- National University of Singapore
- Netherlands Cancer Institute
- New Enterprise Associates
- New Leaf Venture Partners
- New River Management
- NewVa Capital Partners
- Novartis
- Novartis Venture Fund
- Novo Ventures
- ODYSSEE Venture
- ONO Pharmaceutical
- OSEO
- Oberland Capital
- Ohio State University
- Omega Funds
- OnCyte
- Oncodesign Biotechnology
- Onyx Pharmaceuticals
- Opexa Therapeutics
- Opus Bio
- OrbiMed
- Ospedale San Raffaele (San Raffaele Hospital)
- OspedalePediatrico Bambino Gesù (Bambino Gesù Children's Hospital)
- Oxford BioMedica
- PLA General Hospital
- Partners Innovation Fund
- Peking University
- Perceptive Bioscience Investments
- PersonGen Biomedicine (Suzhou)
- Peter MacCallum Cancer Centre
- Pfizer
- PharmaCell
- Pharmacyclics
- Pierre Fabre Group
- Polaris Partners
- PolyBioCept
- Pontifax
- Poseida Therapeutics
- Precision BioSciences
- Pregenen
- Progenitor Cell Therapy
- Prometheus Laboratories
- QVT Financial
- QueensBridge Venture Partners
- Quogue Capital
- RA Capital Management
- Ramius Capital Group
- Redmile Group
- RedoxTherapies
- Regeneron Pharmaceuticals
- Remeditex Ventures
- Renji Hospital
- Ridgeback Capital Management
- Ridgeway Capital Partners
- Riverbank Capital Securities
- Roche
- Rock Springs Capital
- Rockland Immunochemicals
- Roger Williams Medical Center
- Roswell Park Cancer Institute
- Royal Adelaide Hospital Cancer Center
- SOLTI Breast Cancer Research Group
- SOTIO
- SR One
- Sabby Management
- Sanford Research
- SangamoBioSciences
- Sanofi Aventis
- Sanofi-Genzyme BioVentures
- Schering-Plough
- Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
- Seattle Children's Hospital
- Seattle Genetics
- Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- Second Military Medical University
- Sectoral Asset Management
- Servier
- Shanghai Cancer Institute
- Shanghai Chest Hospital
- Shanghai Genechem
- Sheba Medical Center
- Shenzhen Institute for Innovation and Translational Medicine
- Shenzhen Second People's Hospital
- Shionogi
- Sichuan University
- Sidney Kimmel Comprehensive Cancer Center
- Sinobioway Cell Therapy
- Sorrento Therapeutics
- Southwest Hospital
- Spectrum Pharmaceuticals
- St. Jude Children's Research Hospital
- Stage Cell Therapeutics
- Stanford University
- Stifel
- Sun Yat-Sen University
- Super-T Cell Cancer Company
- Syncona
- T-Cell Factory
- T. Rowe Price Associates
- TILT Biotherapeutics
- TNK Therapeutics
- TRACT Therapeutics
- TVAX Biomedical
- TVM Capital
- Takara Biosciences
- Targazyme
- Techno Venture Management
- Tel Aviv Sourasky Medical Center
- Terumo
- Tessa Therapeutics
- Tethys Holdings
- Texas Emerging Technology Fund
- The Clinical Cell and Vaccine Production Facility
- Theravectys
- Thermo Fisher Scientific
- Third Military Medical University
- Third Rock Ventures
- Third Security
- Three Arch Opportunity Fund
- TiGenix
- Tianjin Medical University Cancer Institute and Hospital
- Tmunity Therapeutics
- Tongji Hospital
- Tongji University School of Medicine
- Transposagen Biopharmaceuticals
- TriumviraImmunologics
- Two Blades Foundation
- TxCell
- UCLA Jonsson Comprehensive Cancer Center
- UNC Lineberger Comprehensive Cancer Center
- United Therapeutics
- UniQure
- Universal Cells
- University College London
- University Health Network, Toronto
- University Medical Center Utrecht
- University of Birmingham
- University of California, Berkeley
- University of Florida
- University of Lausanne
- University of Milano-Bicocca
- University of Minnesota
- University of Oxford
- University of Pennsylvania
- University of Zurich
- Unum Therapeutics
- Uppsala University
- Utrecht Holdings
- VGXI
- Vaccinogen
- Valeant Pharmaceuticals
- VenBio
- Venrock
- Versant Ventures
- Vertex
- Vical
- Viking Global Investors
- ViroMed
- VorBiopharma
- Weill Cornell Graduate School of Medical Sciences
- Wellington Management
- West China Hospital
- Woodford Investment Management
- WuXiAppTec
- Wunderlich
- Wyeth (Pfizer)
- X-Body
- Xijing Hospital
- Xinqiao Hospital
- Xuzhou Medical College
- ZIOPHARM Oncology
- Zhujiang Hospital
For more information about this report visit http://www.researchandmarkets.com/research/9dft7v/tcell